Nelivaptan
chemical compound
Nelivaptan (INNTooltip International Nonproprietary Name; developmental code names SSR-149415, NB-415, and BH-200) is a selective, orally active, non-peptide vasopressin V1B receptor antagonist. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted. Subsequently, nelivaptan was developed by Nelivabon for treatment of depressive disorders under the code name NB-145, but development was discontinued in 2022. However, it is also under development by HMNC Brain Health for major depressive disorder under the code name BH-200, and is in phase 2 trials for this indication as of August 2025.
Begin with the source’s own compact description: “Nelivaptan” is chemical compound. The dossier treats that line as a proposition to test through Nelivaptan, chemical and compound, not as a finished interpretation.
Why this record matters
The phrase “chemical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 29, 2026. The linked authority identifier is Q6989992. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2008, 2022 and 2025.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Nelivaptan”, its source revision and the description used here.
- Expand the search: follow Nelivaptan primary sources, Nelivaptan archive and Nelivaptan research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Nelivaptan”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Nelivaptan” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.